ATH434 protects brain cells and improves motor function in Parkinsonian disorder
Oral presentation at the American Academy of Neurology
News provided by
Share this article
MELBOURNE, Australia
, April 21, 2021 /PRNewswire/ Alterity Therapeutics (ASX: ATH,NASDAQ: ATHE) ( Alterity or the Company ) today announced an oral presentation of expanded animal data to support the commercialisation of its lead compound ATH434 in clinical development for the treatment of Parkinsonian disorders, at the American Academy of Neurology (AAN) virtual annual meeting.
The AAN conference, held this week, is the world s preeminent clinical and scientific conference in the neurology space. The presentation titled
ATH434 Preserves Dopaminergic Neurons, Reduces α-synuclein Oligomerization, and Improves Motor Function in a Transgenic Murine Multiple System Atrophy Model
(ATHE) - Alterity s Stock Is Trading Higher As ATH434 Preserves Neurons, Motor Performance In Animal Model With Neurodegenerative Disorder
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
Novel Sleep Biomarkers Linked to Neurodegenerative Disease
tullahomanews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tullahomanews.com Daily Mail and Mail on Sunday newspapers.
Jazz Pharmaceuticals (JAZZ) Presents Phase 3 Study Results of Xywav Oral Solution in Adult Patients with Idiopathic Hypersomnia at AAN
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Global Dementia Drugs Market Expected to Exceed $19.6 Billion In 2026
- FinancialNewsMedia.com News Commentary
PALM BEACH, Fla., April 20, 2021 /PRNewswire/ While this past year living in quarantine during the pandemic did not just create economical damage, and social disruption… it could have also increased new cases of secondary medical results from the pandemic. According to various reports the outbreak of the COVID-19 pandemic is expected to have a significant impact on the Dementia drugs market. According to a research study by Katya Numbers et al., published in Nature Reviews Neurology, in January 2021, the population with dementia are at high risk of contracting COVID-19 infection as the cognitive symptoms cause difficulty to abide by the safety guidelines that were proposed to contain the viral spread. Furthermore, older populations with dementia are also more likely to have more severe disease consequences than those without dementia. Additionally, the statement from